|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 血清乙型肝炎病毒DNA水平的生物学梯度与肝细胞肝癌的风险性相关显示文摘Context: Serum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B. Objective: To evaluate the relationship between serum HBV DNA level and risk of hepatocellular carcinoma. Design, Setting, and Participants: Prospective cohort study of 3653 participants (aged 30-65 years), who were seropositive for the hepatitis B surface antigen and seronegative for antibodies against the hepatitis C virus, recruited to a community-based cancer screening program in Taiwan between 1991 and 1992. Main Outcome Measure: Incidence of hepatocellular carcinoma during follow-up examination and by data linkage with the national cancer registry and the death certification systems. Results: There were 164 incident cases of hepatocellular carcinoma and 346 deaths during a mean follow-up of 11.4 years and 41 779 person-years of follow-up. The incidence of hepatocellular carcinoma increased with serum HBV DNA level at study entry in a dose-response relationship ranging from 108 per 100 000 person-years for an HBV DNA level of less than 300 copies/mL to 1152 per 100 000 person-years for an HBV DNA level of 1 million copies/mL or greater. The corresponding cumulative incidence rates of hepatocellular carcinoma were 1.3%and 14.9%, respectively. The biological gradient of hepatocellular carcinoma by serum HBV DNA levels remained significant (P< .001) after adjustment for sex, age, cigarette smoking, alcohol consumption, serostatus for the hepatitis B e antigen (HBeAg), serum alanine aminotransferase level, and liver cirrhosis at study entry. The dose-response relationship was most prominent for participants who were seronegative for HBeAg with normal serum alanine aminotransferase levels and no liver cirrhosis at study entry. Participants with persistent elevation of serum HBV DNA level during follow-up had the highest hepatocellular carcinoma risk. Conclusion: Elevated serum HBV DNA level (>10 000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis. | Chen C.-J. Yang H. -I. Su J. 王铮(译) 陈云茹(校) | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，6： | 204 |
| 2 | 恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究显示文摘目的 研究恩替卡韦对拉米夫定治疗失效的慢性乙型肝炎 (CHB)患者的疗效和安全性。方法 采用多中心、随机、双盲、安慰剂对照的临床试验 ,选择拉米夫定治疗失效的CHB病人 14 5例 ,按 4∶1比例随机分为恩替卡韦组 116例 ,安慰剂组 2 9例。完成为期 12周的治疗后 ,检测血清HBVDNA水平、HBeAg和肝生化功能的变化。结果 恩替卡韦组在开始治疗后即有显著的抗病毒效果 ,直至治疗结束。用聚合酶链反应 (PCR ,AmplicorCobas)定量法检测病人HBVDNA的平均下降幅度 ,恩替卡韦和安慰剂组分别为 :4.3 0对数值 (log1 0 )和 0 .15对数值 (log1 0 ) ,P值均 <0 .0 0 0 1;在 12周时 ,用bDNA方法检测 ,两组病人HBVDNA转阴率 (<0 .7mEq ml)为 74%和 10 %。丙氨酸氨基转移酶 (ALT)的复常率为 71%和 7%。两组不良事件的发生率相当 (3 3 %对 2 8% )。无 1例发生药物相关的严重不良反应。结论 用恩替卡韦治疗拉米夫定失效的病人 12周 ,1.0mg d剂量在降低HBVDNA水平和ALT复常方面明显优于安慰剂 。 | 姚光弼 任红 王宝恩 徐道振 周霞秋 | 2005 | 肝脏2005，10，1： | 66 |
| 3 | 应重视HBeAg阴性慢性乙型肝炎的诊断和治疗显示文摘 | 王贵强 | 2005 | 中华内科杂志2005，44，9： | 23 |
| 4 | Relationship between serum HBV DNA level and HBV-specific, nonspecific cytotoxic T lymphocytes and natural killer cells in patients with chronic hepatitis B显示文摘有到对肝炎 B 病毒(HBV ) 的抗病毒的治疗的长期的肝炎 B (CHB ) 的病人的反应与 HBV DNA 的基础线水平有关的背景,而是机制不是清楚的。现在的学习试图理解在 HBV DNA 的水平之间的可能的关系并且HBV特定, nonspecific 细胞毒素的 T 淋巴细胞( CTL )和生来的杀手( NK ) CHB 病人和机制的房间 HBV DNA 水平怎么完全影响抗病毒的治疗学的 effect.Methods 为 HBV DNA 积极的有 CHB 的 100 个成年病人, HBeAg 并且( HLA ) -A2 被注册进这研究。HBV DNA 被实时荧光测试量的聚合酶链反应(PCR ) 。特定的 HBV 和 nonspecific CTL 和 NK 房间被 flowcytometry 测试。浆液丙氨酸 aminotransferase (中高音) 和全部的 bilirubin (Tbil ) 用平淡的生物化学的测试为每个病人被决定。100 个盒子基于他们的 HBV DNA 水平被分到二个组:组 A 有 48 个盒子,他们的 HBV DNA 水平是 104-105 copies/ml,组 B 有 52 个盒子,他们的 HBV DNA 水平是 106-107 copies/ml。 HBV 特定的 CTL , nonspecific CTL , NK 房间,二个组的中高音和 Tbil 是组 A 的 compared.Results HBV DNA 水平, B 是( 4.81 ???????????????????????????????倠???‵??吗????????湯汣獵潩獮?? | GU Xi-bing YANG Xiao-juan WANG Dong HUA Zhong XU Yue-qin LU Zhong-hua | 2009 | Chinese Medical Journal2009，，18： | 23 |
| 5 | Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B显示文摘 | Ming-Hui Li Dan Zhang Lu Zhang Xiao-Jing Qu Yao Lu Ge Shen Shu-Ling Wu Min Chang Ru-Yu Liu Lei-Ping Hu Hong-Xiao Hao Wen-Hao Hua Shu-Jing Song Gang Wan Shun-Ai Liu Yao Xie | 2017 | Chinese Medical Journal2017，，15： | 21 |
| 6 | 枇杷品种早钟6号与解放钟、森尾早生亲缘关系的RAPD分析显示文摘应用43个随机引物对早钟6号、解放钟和森尾早生3个枇杷品种基因组DNA进行RAPD分析,共得到255条扩增带,其中82条为共同带,单态率达32.16%,表明3个品种亲缘关系密切.对子代与父、母本扩增带中共同带的分析表明,双亲的RAPD特征均在子代中表现.用引物S71进行RAPD分析,3个品种共检测出7条扩增带,其中780bp的条带是母本解放钟的特征带,1500bp的条带是父本森尾早生的特征带,在子代早钟6号中这两条特征带同时存在,且结果稳定,在DNA水平上证实了早钟6号是解放钟、森尾早生的有性杂交后代. | 陈义挺 赖钟雄 陈菁瑛 郭玉琼 蔡英卿 郭志雄 吴金寿 黄金松 | 2004 | 福建农林大学学报(自然科学版)2004，33，1： | 21 |
| 7 | Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B显示文摘AIM:To investigate retrospectively the long-term efficacy of various treatment strategies using adefovir dipivoxil(adefovir) in patients with lamivudine-resistant chronic hepatitis B.METHODS:We included 154 consecutive patients in two treatment groups:the 'add-on' group(n = 79),in which adefovir was added to ongoing lamivudine treatment due to lamivudine resistance,and the 'switch/combination' group(n = 75),in which lamivudine was first switched to adefovir and then re-added later as needed.The 'switch/combination' group was then divided into two subgroups depending on whether participants followed(group A,n = 30) or violated(group B,n = 45) a proposed treatment strategy that determined whether to add lamivudine based on the serum hepatitis B virus(HBV) DNA levels(< 60 IU/mL or not) after 6 mo of treatment(roadmap concept).RESULTS:The cumulative probability of virologic response(HBV DNA < 60 IU/mL) was higher in group A than in the 'add-on' group and in group B(P < 0.001).In contrast,the cumulative probability of virologic breakthrough was lower in the 'add-on' group than in group B(P = 0.002).Furthermore,the risk of virologic breakthrough in the multivariate analysis was significantly lower in the 'add-on' group than in group A(hazard ratio = 0.096;95%CI,0.015-0.629;P = 0.015).CONCLUSION:The selective combination of adefovir with lamivudine based upon early treatment responses increased the odds of virologic breakthrough relative to the use of uniform combination therapy from the beginning of treatment. | Tae Jung Yun Jin Yong Jung Chang Ha Kim Soon Ho Um Hyonggin An Yeon Seok Seo Jin Dong Kim Hyung Joon Yim Bora Keum Yong Sik Kim Yoon Tae Jeen Hong Sik Lee Hoon Jai Chun Chang Duck Kim Ho Sang Ryu | 2012 | World Journal of Gastroenterology2012，18，47： | 19 |
| 8 | 树突状细胞亚群相对数与乙型肝炎病毒复制及肝损伤的关系显示文摘目的探讨外周血树突状细胞(DC)亚群相对数量与慢性乙型肝炎(简称慢乙肝)患者血清乙型肝炎病毒(HBV)DNA水平和肝脏病理炎症损伤程度问的关系。方法定量聚合酶链反应法检测患者血清HBV DNA,利用流式细胞仪检测外周血DC亚群。结果血清HBV DNA<106拷贝/ml慢乙肝患者外周血DC2相对数量显著高于HBV DNA≥106拷贝/ml患者和健康者(P<0.05),而后两组间DC2的差异无统计学意义;上述三组中DC1相对数量差异无统计学意义;外周血DC亚群相对数与患者临床型别和肝内炎症损伤程度无关。结论外周血DC2亚群的升高与慢乙肝患者体内HBV低水平复制相关,提示DC2 可能在抑制HBV复制中发挥作用;外周血DC亚群相对数与肝组织炎症程度不相关。 | 高斌 陈红松 赵桂鸣 朱凌 季颖 费然 戴晨阳 徐健 朱理珉 魏来 | 2005 | 中华肝脏病杂志2005，13，6： | 17 |
| 9 | 母体HBV传染性与宫内感染的探讨显示文摘目的 探讨母体HBV传染性与宫内感染的关系。方法 于 1999年 12月~ 2 0 0 2年 6月 ,将我院HBsAg阳性孕妇 12 2例 ,分为 3组 :HBIG组 4 9例 ;拉米夫定组 4 5例 ;对照组 2 8例。HBIG组孕妇自孕 2 8w起肌内注射HBIG 2 0 0U ,每4w一次至分娩 ;拉米夫定组自孕 2 8w始每日口服拉米夫定 10 0mg直至分娩后 4w ;对照组未予用药。三组孕妇均于孕 2 8w用药前及分娩前行血乙肝两对半及HBVDNA定量检测 ,新生儿出生后 2 4h内予HBIG 10 0U注射 ,并予HBVac 0 ,1,6方案接种 ,新生儿出生后 2 4h内免疫接种前采静脉血检测血乙肝两对半及HBVDNA定量。结果 孕 2 8w时孕妇不同的HBVDNA水平其宫内感染率差异无显著性 (P >0 .1) ;而胎儿宫内感染率随着孕妇分娩前血清HBVDNA含量的增加呈增高趋势 (P<0 .0 1)。结论 宫内感染的发生率与孕妇孕期HBV传染性相关 ,孕期高病毒血症 (即HBVDNA≥ 10 8copies/ml)与宫内感染显著相关。 | 杨越波 李小毛 侯红瑛 沈慧敏 滕奔琦 马琳 | 2004 | 中国优生与遗传杂志2004，12，2： | 17 |
| 10 | 化学发光法与ELISA法对乙肝两对半少见模式测定的比较分析显示文摘 | 刘灿 陈静 李雯 | 2007 | 中国实验诊断学2007，11，12： | 16 |
| 11 | Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures显示文摘AIM:To evaluate the efficacy and safety of tenofovir disoproxil fumarate(TDF) for chronic hepatitis B(CHB) patients after multiple failures.METHODS:A total of 29 CHB patients who had a suboptimal response or developed resistance to two or more previous nucleoside/nucleotide analogue(NA) treatments were included.Study subjects were treated with TDF alone(n = 13) or in combination with lamivudine(LAM,n = 12) or entecavir(ETV,n = 4) for ≥ 6 mo.Complete virologic response(CVR) was defined as an achievement of serum hepatitis B virus(HBV) DNA level ≤ 60 IU/mL by real-time polymerase chain reaction method during treatment.Safety assessment was based on serum creatinine and phosphorus level.Eleven patients had histories of LAM and adefovir dipivoxil(ADV) treatment and 18 patients were exposed to LAM,ADV,and ETV.Twenty-seven patients(93.1%) were hepatitis B e antigen(HBeAg) positive and the mean value of the baseline serum HBV DNA level was 5.5 log IU/mL ± 1.7 log IU/mL.The median treatment duration was 16 mo(range 7 to 29 mo).RESULTS:All the patients had been treated with LAM and developed genotypic and phenotypic resistance to it.Resistance to ADV was present in 7 patients and 10 subjects had a resistance to ETV.One patient had a resistance to both ADV and ETV.The cumulative probabilities of CVR at 12 and 24 mo of TDF containing treatment regimen calculated by the Kaplan Meier method were 86.2% and 96.6%,respectively.Although one patient failed to achieve CVR,serum HBV DNA level decreased by 3.9 log IU/mL from the baseline and the last serum HBV DNA level during treatment was 85 IU/mL,achieving near CVR.No patients in this study showed viral breakthrough or primary non-response during the follow-up period.The cumulative probability of HBeAg clearance in the 27 HBeAg positive patients was 7.4%,12%,and 27% at 6,12,and 18 mo of treatment,respectively.Treatment efficacy of TDF containing regimen was not statistically different according to the presence of specific HBV mutations.History of prior exposure to specific antiviral agents did not make a difference to treatment outcome.Treatment efficacy of TDF was not affected by combination therapy with LAM or ETV.No patient developed renal toxicity and no cases of hypophosphatemia associated with TDF therapy were observed.There were no other adverse events related to TDF therapy observed in the study subjects.CONCLUSION:TDF can be an effective and safe rescue therapy in CHB patients after multiple NA therapy failures. | Yu Jin Kim Dong Hyun Sinn Geum-Youn Gwak Moon Seok Choi Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo Joon Hyeok Lee | 2012 | World Journal of Gastroenterology2012，18，47： | 16 |
| 12 | Efficacy of Real-world Entecavir Therapy in Treatment-naive Chronic Hepatitis B Patients显示文摘 | Yan-Di Xie Hui Ma Bo Feng Lai Wei | 2017 | Chinese Medical Journal2017，，18： | 16 |
| 13 | 分子标记在竹类植物遗传多样性保护中的应用显示文摘竹类植物与人类的生存和生活密切相关,对其在DNA水平上的遗传多样性研究具有重要的理论和实践意义。分子标记是基因型的特殊的易于识别的表现形式,它是生物分类学、育种学、遗传学和物种起源与进化等研究的主要技术指标之一。本文综述了几种常用的DNA分子标记(RFLP、RAPD、AFLP等)在竹类植物种质资源鉴定、分类、亲缘关系、遗传多样性和起源进化等方面的研究进展,同时进一步展望了分子标记在濒危竹种保护和研究中的应用前景。 | 邢新婷 江泽慧 | 2004 | 世界竹藤通讯2004，2，3： | 14 |
| 14 | 无症状HBV携带者血清HBVDNA水平与肝组织炎症活动度的关系显示文摘目的探讨无症状HBV携带者(AsC)肝脏病理损害程度与血清HBVDNA水平的关系。方法对139例AsC于超声引导下采用美国生产的DARD自动活检枪经皮肝穿刺行病理学检查;HBVDNA用PCR测定。结果139例AsC中G1者94例,G2者26例,G3者19例,无G0和G4者;血清HBVDNA水平与肝组织炎症活动度间无显著性差异(P>0.05);HBeAg阴性组G3者所占比例大于HBeAg(+)组(P=0.019)。结论AsC肝脏均有不同程度损害,其损害程度与HBVDNA水平无相关性。 | 陈国良 吴丽 | 2005 | 实用肝脏病杂志2005，8，3： | 14 |
| 15 | HBV感染血清标志物、HBV DNA水平与性别的关系显示文摘探讨HBV感染者血清标志物、HBVDNA水平和性别之间的关系。选择 4 95例HBsAg阳性的血清标本和5 0 2例HBVDNA高于 1× 10 8copy/ml以上的血清标本 ,分别通过ELISA法以及实时荧光定量法进行HBV感染血清标志物HBVDNA的检测。三种组合〔组合 1为HBsAg(+)HBeAg(+)抗 -HBc(+) ,组合 2为HBsAg(+)抗 -HBe(+)抗 -HBc(+) ,组合 3为HBsAg(+)抗 -HBc(+)〕的HBVDNA阳性率 (分别为 95 %、18%和 5 3% )存在极显著差异 (P <0 0 1) ;女性在HBeAg阴性模式中的比例与在HBeAg阳性模式中的比例差异显著 (P <0 0 5 )。HBV感染血清标志物、HBVDNA水平和性别之间存在着重要的关系 ;对于组合 3的患者要给予足够重视 ;女性在高HBVDNA水平而且HBeAg阴性组合中的比例非常小 ,这也许与女性在肝癌患者中所占比例较低存在着一定的关系。 | 皮斌 田德英 | 2004 | 临床肝胆病杂志2004，20，1： | 14 |
| 16 | 中国狗牙根(Cynodon dactylon)优良选系的RAPD分析显示文摘对采自中国不同地区的6份狗牙根〔Cynodondactylon(L.)Pers.〕优良选系进行了RAPD分子标记实验。选用15个引物共扩增出438条带,平均每个引物扩增出29条带,其中多态性带415条,多态性位点百分率达到59.02%~75.49%。各选系间遗传相似性系数差异较大(0.408~0.672),说明各选系间在DNA水平上存在着丰富的遗传多样性,与新品种C106(爬地青)相比,各选系还存在一定的改良空间。实验结果也表明,RAPD分子标记可成功地用于中国狗牙根优良选系遗传多样性的研究及品种鉴定。 | 郑玉红 刘建秀 陈树元 | 2005 | 植物资源与环境学报2005，14，2： | 13 |
| 17 | De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients显示文摘AIM:To investigate the appropriate time for combination therapy in HBeAg positive chronic hepatitis B(CHB) patients with decompensated cirrhosis.METHODS:Thirty HBeAg positive CHB patients with decompensated cirrhosis were enrolled in the study.All of the patients were given 48 wk combination therapy with lamivudine(LAM) and adefovir dipivoxil(ADV) .Briefly,10 patients were given the de novo combination therapy with LAM and ADV,whereas the other 20 patients received ADV in addition to LAM after hepatitis B virus(HBV) genetic mutation.RESULTS:Serum alanine aminotransferase and total bilirubin were both improved in the two groups at 4,12,24 and 48 wk after treatment.Serum albumin was also improved at 24 and 48 wk after combination therapy in both groups.The serum HBV DNA level wasstill detectable in every patient in the two groups at 4 and 12 wk after combination treatment.However,in the de novo combination group,serum HBV DNA levels in 4(40%) and 9(90%) patients was decreased to below 1×10 3 copies/mL at 24 and 48 wk after the combination treatment,respectively.In parallel,serum HBV DNA levels in 2(20%) and 8(40%) patients in the add-on combination group became undetectable at 24 and 48 wk after combination treatment,respectively.Furthermore,6(60%) patients in the de novo combination group achieved HBeAg seroconversion after 48 wk treatment,whereas only 4(20%) patients in the add-on combination group achieved seroconversion.Child-Pugh score of patients in the de novo combination group was better than that of patients in the add-on combination group after 48 wk treatment.Moreover,patients in the de novo combination group had a significantly decreased serum creatinine level and elevated red blood cell counts.CONCLUSION:De novo combination therapy with LAM and ADV was better than add-on combination therapy in terms of Child-Pugh score,virus inhibition and renal function. | Xiao-Hong Fan Jian-Zhang Geng Li-Fen Wang Ying-Ying Zheng Hai-Ying Lu Jing Li Xiao-Yuan Xu | 2011 | World Journal of Gastroenterology2011，17，43： | 12 |
| 18 | 转基因大豆及制品中转基因成分检测技术研究进展显示文摘转基因技术是提高农作物产量和降低生产成本的主要途径,但转基因植物及其制成品存在的安全性和环境问题也越来越受到人们的关注。目前,已有30多个国家制定了相关的法律法规对转基因作物及其衍生产品进行标志。近年来,我国的转基因大豆及其制品消费量越来越大,迫切需要合适的检测手段以确定大豆及其制品中是否含有转基因成分及其含量。本文总结了各种转基因大豆及其制品转基因成分检测技术及其最新发展,提出了快速化和精确定量是未来转基因成分检测技术的发展方向。 | 蒋亦武 黄明 王保战 杭宝建 何健 李顺鹏 | 2011 | 江苏农业科学2011，39，1： | 11 |
| 19 | Effects of the Ganning Formula (肝宁方) on Liver Fibrosis in Patients With Chronic Hepatitis B显示文摘Objective: To investigate the clinical efficacy and safety of the Ganning formula (肝宁方) for the treatment of liver fibrosis in patients with chronic hepatitis B. Methods: In a multicenter, randomized, controlled clinical trial, 150 patients with liver fibrosis secondary to hepatitis B virus (HBV) infection were randomly assigned in equal numbers to receive either the Ganning formula (a Chinese herbal decoction; active treatment group) or oral entecavir (control group) for two 3-month courses. Patients were monitored for any treatment-induced changes in liver function test parameters (ALT, AST, and GGT), liver fibrosis markers (LN, HA, IV-C, and PCIII), HBV DNA level, hepatosplenic imaging, quality of life scores, or psychological and social functioning scores. Patients were also observed for any adverse effects. Results: After treatment, patients in both groups experienced significant improvements in liver function, HBV DNA load, hepatosplenic B-mode ultrasonography, quality of life, and psychological and social functioning (P<0.05 or P<0.01). Patients receiving the Ganning formula achieved greater improvements in HA, IV-C, quality of life, and psychological and social functioning compared with those on entecavir (P<0.05 or P<0.01). There were no abnormal changes in blood tests, urine, feces, renal function, or electrocardiogram. Additionally, no adverse effects were observed in any patients in either group. Conclusions: The Ganning formula appears to have the potential to inhibit liver fibrosis and therefore improve liver function by inhibiting HBV replication in patients with chronic hepatitis B. Additionally, this formula is helpful in improving quality of life and psychological and social functioning. | 邓鑫 梁健 吴发胜 李艳波 唐艳芳 | 2011 | Journal of Traditional Chinese Medicine2011，31，4： | 11 |
| 20 | 乙型肝炎病毒基因型与血清HBV DNA水平的关系显示文摘目的 探讨乙型肝炎病毒 (HBV)基因型与血清HBVDNA水平的关系。方法 采用PCR、核酸杂交和酶联显色技术以及荧光定量PCR技术 ,分别对 12 3例慢性乙型肝炎 (CHB)患者进行HBVDNA基因分型和血清HBVDNA水平的测定。结果 泉州地区CHB患者的HBV基因型以B型为主 ,其次为C型 ,部分以D型和混合型存在 ,分别占 74 80 %、17 0 7%、3 2 5 %和 5 69% ,无A、E、F型。C基因型的HBVDNA水平 (log值 )为 7 0 5± 1 3 5 ,显著高于B基因型的 6 3 2± 1 0 6,P <0 0 1;而C基因型的HBeAg含量为5 3 62± 2 5 3 2 ,亦显著高于B基因型的 40 1l± 15 17,P <0 0 1。C基因型患者的TBIL、ALT、AST均显著高于B基因型 ,而白蛋白水平则显著低于B基因型 ,P <0 0 1。结论 泉州地区CHB患者以B基因型为主 ,部分以C型、D型和混合型存在。C基因型的血清HBVDNA水平显著高于B型 。 | 张启华 杨红 许正锯 陈先礼 黄以群 王崇国 | 2004 | 胃肠病学和肝病学杂志2004，13，5： | 11 |
您所在的机构暂未开通此部分的功能，请联系管理员